FINVASIA-GROUP
18.4.2022 10:32:08 CEST | Business Wire | Press release
Finvasia today announced that it has appointed Tajinder Virk as the interim Chief Executive Officer for ZuluTrade. He will replace the previous CEO from the company, effective immediately.
"Tajinder has been instrumental in building upon Finvaisa’s success and has an impressive track record in delivering growth for our group companies," said Sarvjeet Singh Virk, CMD & Co-founder Finvasia. "We have seen Tajinder (A.K.A. Natty) in action first hand and have the utmost confidence that his deep financial experience and leadership skills will drive results and accelerate ZuluTrade’s business in this interim role."
Tajinder Virk is the CEO of Finvasia Group of companies and is an exceptional leader with deep familiarity with all aspects of the business that allows him to develop and lead the execution of the group’s strategic vision, assess risks and guide the group’s growth. He has worked with some of the largest investment banks and hedge funds on Wall Street and has managed multibillion-dollar funds for major US banks, before co-founding Finvasia. At ZuluTrade, Tajinder will work closely with the team to deliver on the business expansion plan.
Commenting on the appointment, Tajinder said, “Finvasia is known for its innovative business approach and for its ability to create value for its clients. We see ZuluTrade as the largest Social Wealth Management platform that will bring more asset classes and industry participants together under a single platform.
“ZuluTrade is among the largest and the original social trading platforms that revolutionised copy trading in 2008. ZuluTrade 2.0 will maintain its legacy of being broker neutral, so it has no conflict of interest with its investors. We will be offering a variety of asset classes, encouraging more investors, leaders and brokers to join the platform whilst creating a conducive environment for them to grow their wealth,” he continued.
Finvasia’s board has simultaneously commenced a formal search for a permanent CEO for ZuluTrade who can deliver on the Group’s expectations for future ready products while maintaining its core values and cultures.
About ZULUTRADE (https://www.zulutrade.com )
ZuluTrade is the original social trading platform that revolutionised copy trading in 2008. It offers a massive database of Algo signals and strategies currently available across the market, catering to both advanced and novice investors alike.
It's a broker neutral platform that has catered to over 2.5 million clients in over 100 countries and supports over twenty-six languages.
About FINVASIA (https://finvasia.com )
Finvasia is a multi-disciplinary, multinational organisation that owns and operates over a dozen brands across financial services, technology, real estate and healthcare verticals.
Finvasia Group has managed funds for some of the notable hedge funds of Wall street, launched the first and only commission free ecosystem for financial products in India and is now aggressively expanding its presence in the European market. The Group has provided technology to some of the notable listed and unlisted financial services entities across the globe.
Furthermore, its healthcare division recently launched a medically proven diabetes reversal program in India and has engaged scientists from various specialised fields in an effort to build nano and micro medical devices that will cater to the future of medical engineering.
In the last 13 years, Finvasia has catered to a few million clients in over 180 countries directly or via its subsidiaries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220418005251/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kiabi Selects Navan to Centralise Global Travel Program11.5.2026 09:00:00 CEST | Press release
Fashion retailer targets high employee adoption and efficiency with AI-powered travel platform Navan (NASDAQ: NAVN), the global AI-powered business travel and expense platform, today announced it has been selected by Kiabi, the French multinational fashion retailer, to consolidate its global travel with one unified platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260511547434/en/ Fashion retailer targets high employee adoption and efficiency with AI-powered travel platform To support its workforce of nearly 10,000 “Kiabers,” the retailer required a solution capable of providing an easy-to-use travel platform. Navan was selected due to its intuitive AI-powered interface and ability to integrate with Kiabi’s travel policies directly in-app. “Managing travel was becoming an administrative burden that slowed our teams down,” said Denise Maurice, Indirect Procurement Director at Kiabi. “We wanted to give our ‘Kiabers’ the
Owl Labs partners with Westcoast to expand access to seamless hybrid meeting experiences in the UK and Ireland11.5.2026 09:00:00 CEST | Press release
Partnership aims to reduce the ‘meeting tax’ by expanding access to Owl Labs products through Westcoast’s extensive distribution network Owl Labs, a global leader in AI-powered, 360-degree video conferencing solutions, today announced a new UK and Ireland distribution partnership with Westcoast Limited, one of the country’s largest and most trusted IT distributors. The agreement will see Westcoast distribute the full range of Owl Labs’ award-winning Meeting Owl and Owl Bar products across the UK and Ireland, providing greater choice, availability, and dedicated support for resellers and end customers navigating the demands of hybrid work. The partnership aims to address the technical setup challenges that plague meetings across the UK. Owl Labs’ recent State of Hybrid Work report found that nearly 8 in 10 workers (79%) lose time in meetings due to technical difficulties such as connecting to a meeting or setting up a camera. By making Owl Labs’ solutions simpler to source, deploy and s
Fujirebio Announces CE Marking of the Fully Automated Lumipulse® G pTau 217 Plasma Assay11.5.2026 09:00:00 CEST | Press release
H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that Fujirebio Europe N.V. has obtained a CE certificate of the Lumipulse G pTau 217 Plasma assay under the Regulation (EU) 2017/746 on in vitro diagnostic medical devices (IVDR). This CLEIA (chemiluminescent enzyme immunoassay) test allows for the quantitative measurement of Tau phosphorylated at threonine 217 (pTau 217) in human plasma (K2EDTA). “With Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma now CE‑marked on our LUMIPULSE G platform, we are advancing a new era of neurology diagnostics—one where blood‑based biomarkers enable earlier, broader, and more accessible insights into Alzheimer’s disease and neurodegeneration.” said Christiaan De Wilde, CEO at Fujirebio Europe N.V. “By delivering fully automated and scalable solutions, we are helping clinicians move decisively toward more timely and informed decision‑making. This milestone underscores our long‑term vision to reimagine the diagnostic
Mevion Introduces the First Proton Therapy System Designed for a LINAC Vault at ESTRO 202611.5.2026 08:00:00 CEST | Press release
The MEVION S250-FIT™ creates a new pathway for European cancer centers to integrate proton therapy into existing radiotherapy programs Proton therapy is entering the LINAC vault. At ESTRO 2026, Mevion Medical Systems will introduce the MEVION S250-FIT Proton Therapy System to the European radiation oncology community, the first proton therapy system designed for installation in a standard radiation therapy vault. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507172087/en/ The MEVION S250-FIT™ Proton Therapy System Now both U.S. FDA-cleared and CE-marked under Regulation (EU) 2017/745, the S250-FIT creates a new pathway for cancer centers to bring proton therapy into existing LINAC-based treatment environments, aligning advanced proton capability with the infrastructure, workflows, and capital planning of modern radiation oncology. Stanford Medicine: First S250-FIT Installation On April 7, 2026, Stanford Medicine unveiled
Vedanta FY26 Profit Soars by 22% to $2.8 bn; Enters Demerger Phase11.5.2026 02:30:00 CEST | Press release
India-based Vedanta Limited (BSE: 500295 & NSE: VEDL), a global leader in metals, oil & gas, critical minerals, power and technology, announced its results for the fourth quarter and full year ended 31 March 2026. It has delivered its best-ever financial performance, driven by structurally strong businesses and disciplined execution. For the full year, Vedanta’s Profit stood at an all-time high of $2.8 bn, reflecting a 22% YoY increase and a profit of $1 bn in Q4 FY26, up nearly 90% YoY. Vedanta reported its highest-ever annual revenue of about $20 bn, up 15% YoY, with Q4 revenue at $5.6 bn, an increase of nearly 30% YoY. The Company maintained strong cost leadership, contributing to record EBITDA of $6.3 bn for FY26, up by about 30% YoY, with margins expanding to around 40%. Q4 EBITDA stood at $2.0 bn, up by nearly 60% YoY, with a margin of approximately 44%. The balance sheet strengthened further, with Net Debt/EBITDA improving to 0.95x, supported by strong cash generation. Underscor
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
